On Monday, Piper Sandler reaffirmed its Overweight rating on Allogene Therapeutics (NASDAQ:ALLO) stock with a price target of $11.00. The firm's analysis follows recent presentations at medical conferences that highlighted the potential of CAR-T therapies in autoimmune diseases.
Despite a tepid response from investors to data sets presented at the European League Against Rheumatism (EULAR) on Friday, an oral presentation at the European Hematology Association (EHA) on Saturday showcased promising data from Schett Lab, indicating strong results in lupus and two other autoimmune indications.
Allogene Therapeutics is at the forefront of developing CAR-T therapies, a type of treatment that modifies a patient's T-cells to attack cancer cells. The company's research into autoimmune diseases represents a potential expansion of this technology beyond oncology.
Piper Sandler's commentary suggests that Allogene's ALLO-329, which targets both CD19 and CD70, could offer clinical benefits such as durability and reduced need for lymphodepletion, a process that weakens the immune system.
ALLO-329 is poised to be a pioneering therapy in the CAR-T space, with a dual-targeted approach that may provide an advantage in treating autoimmune diseases. The start of Phase 1 trials for ALLO-329 is scheduled for the first half of 2025, which could mark a significant milestone for Allogene Therapeutics in its pursuit of innovative treatments.
The reaffirmation of the Overweight rating and the $11.00 price target by Piper Sandler indicates confidence in Allogene's strategic direction and the potential of its pipeline. The company's focus on CAR-T therapies for autoimmune diseases could set it apart in a competitive biotech landscape.
Investors and industry watchers will likely keep a close eye on Allogene's progress, especially as it approaches the commencement of Phase 1 trials for its ALLO-329 therapy. The developments in CAR-T applications for autoimmune diseases could have implications for both the company's future and the broader therapeutic field.
In other recent news, Allogene Therapeutics has been a focal point for various analyst firms. The company has seen mixed financial results, with a strong cash position of $397.3 million at the end of Q1 2024, despite higher-than-expected R&D and SG&A expenses.
Allogene's strategic initiatives, such as the expansion of commercial rights for cema-cel, a key drug candidate, to the European Union and the United Kingdom, have been well received. This move increases the potential total addressable market to over $9.5 billion, a significant development that could potentially enhance future revenues.
The company is also making strides in its clinical trials, with the ALPHA3 pivotal trial for cema-cel set to begin enrollment in mid-2024. This trial aims to establish the drug as a consolidation therapy for MRD+ LBCL patients. Analysts have offered varied perspectives on Allogene's future, with ratings ranging from "Market Perform" to "Outperform."
Furthermore, Allogene recently raised approximately $110 million in funding, which is expected to extend the company’s cash runway through 2026. However, several analyst firms have adjusted their price targets for Allogene, including Oppenheimer, which lowered its target to $13, H.C. Wainwright, which reduced its target to $9, and B.Riley, which cut its target to $7. Despite these adjustments, each of these firms maintains a positive rating on the stock.
These are recent developments that investors should take into account when considering Allogene Therapeutics.
InvestingPro Insights
Piper Sandler's optimistic outlook on Allogene Therapeutics is echoed by some of the metrics and analyst activities tracked by InvestingPro. With a market capitalization of $490.64M, Allogene is a notable player in the biotech industry, albeit one that is facing challenges. The company's strategic focus on CAR-T therapies for autoimmune diseases is an innovative move, but it's important to note the financial aspects that accompany this endeavor. Allogene holds more cash than debt on its balance sheet, which is a positive sign for its financial health and ability to fund ongoing research. Additionally, the fact that 8 analysts have revised their earnings upwards for the upcoming period suggests growing confidence in the company's potential despite current setbacks.
However, investors should be aware of the company's cash burn and weak gross profit margins, as these factors could impact the timeline and success of bringing therapies like ALLO-329 to market. Allogene is not expected to be profitable this year and has not been profitable over the last twelve months, which is typical for many biotech companies in the research and development phase. Moreover, the stock has experienced a significant price drop over the last three months, trading near its 52-week low. For those looking for a more in-depth analysis, there are additional InvestingPro Tips available on the platform, providing a comprehensive look at Allogene's financial and operational standing.
To gain further insights and access to exclusive tips that could guide investment decisions, readers can consider an InvestingPro subscription. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.